DAPZURA RT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DAPZURA RT (DAPZURA RT).
Selective estrogen receptor degrader (SERD) and antagonist; binds to estrogen receptor alpha (ERα), induces its degradation, and inhibits estrogen-dependent growth.
| Metabolism | Primarily metabolized by CYP3A4 and UGT1A9; minor contribution from CYP2C9. |
| Excretion | Primarily renal: 70-80% unchanged in urine; biliary/fecal excretion accounts for 10-15% as metabolites. |
| Half-life | Terminal elimination half-life: 12-15 hours (sufficient for once-daily dosing in most patients; prolonged in renal impairment). |
| Protein binding | High: >99% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: 1.5-2.0 L/kg (indicates extensive tissue distribution). |
| Bioavailability | Oral: 78-85% (with high-fat meal decreases absorption slightly). |
| Onset of Action | Oral: within 1-2 hours (max glycemic effect at 4-6 hours). |
| Duration of Action | Oral: 24 hours (supports once-daily dosing; effects may persist longer in renal impairment). |
20 mg orally once daily
| Dosage form | POWDER |
| Renal impairment | GFR ≥30 mL/min: no adjustment; GFR 15-29 mL/min: 10 mg once daily; GFR <15 mL/min: not recommended |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: not recommended; Child-Pugh Class C: contraindicated |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established |
| Geriatric use | No dose adjustment required based on age alone; monitor renal function and consider age-related decline in GFR |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DAPZURA RT (DAPZURA RT).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Baloxavir marboxil and its active metabolite are likely excreted in animal milk. M/P ratio is unknown. Caution is advised; consider the benefits of breastfeeding, the mother's need for treatment, and potential infant exposure. |
| Teratogenic Risk | Dapzura RT (baloxavir marboxil) is a cap-dependent endonuclease inhibitor. Human data are limited. In animal studies, no fetal harm was observed at exposures up to 3 times the human clinical exposure. First trimester: Limited data, but based on animal studies, risk cannot be excluded. Second and third trimesters: Insufficient data; however, no structural anomalies reported in limited human cases. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to daprodustat or excipients.","Pregnancy.","Uncontrolled hypertension."]
| Precautions | ["Dyslipidemia: Monitor lipid profile.","Hepatic effects: Monitor liver function; dose adjustment needed for moderate to severe impairment.","Fetal harm: Can cause fetal harm if used during pregnancy; advise effective contraception.","Gastrointestinal toxicity: Increased risk of diarrhea, nausea, vomiting; manage with supportive care."] |
| Food/Dietary | No specific food interactions. Can be taken with or without food. Avoid excessive alcohol consumption due to risk of ketoacidosis. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required for Dapzura RT. Standard prenatal care. Monitor maternal influenza symptoms and adverse effects. No known fetal ultrasound abnormalities associated. |
| Fertility Effects | In animal studies, no impairment of fertility was observed at exposures up to 3 times the human clinical exposure. Human data are insufficient to determine effects on fertility. |
| Clinical Pearls |
| DAPZURA RT (dapagliflozin) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. Monitor renal function before initiation and periodically; contraindicated if eGFR <25 mL/min/1.73 m². Assess volume status in elderly or patients on diuretics. Risk of euglycemic ketoacidosis; discontinue if metabolic acidosis suspected. Do not use in type 1 diabetes. Can reduce uric acid levels. |
| Patient Advice | Take oral tablets regardless of meals, swallowing whole. · Do not crush or chew the extended-release tablets. · Drink adequate fluids to prevent dehydration and hypotension. · Monitor for signs of ketoacidosis: nausea, vomiting, abdominal pain, confusion, excessive thirst. · Report any genital infections (yeast, balanitis) or urinary tract infections. · Avoid alcohol? No specific restriction; moderate intake advised. · Do not use if pregnant or breastfeeding; discuss contraception if of childbearing potential. · Check blood glucose regularly as per your healthcare provider's recommendation. |